Authors
Panupong Wangprapa, Dorottya Nagy-Szakal, Heather L Wells, Gabor Fidler, Wichai Techasathit, Mara Couto-Rodriguez, David C Danko, Christopher E Mason, Niamh B O'Hara, Montinee Sangtian, Teeradache Viangteeravat, Sira Sriswasdi
Published in
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Pages 109181. Oct 14, 2026. Epub Oct 14, 2026.
Abstract
Culture and antimicrobial susceptibility testing (AST) take 48-72 hours, leaving empirical therapy for urinary tract infections (UTIs) without resistance data. Metagenomic next-generation sequencing (mNGS) reports resistance within hours, but its potential clinical actionability for prescribing is underexplored.
In a retrospective single-centre cohort (Bangkok tertiary hospital, 2018-2020), BIOTIA-DX results were compared with culture and AST in 251 culture-paired samples. Potential clinical actionability was assessed for 54 same-day empirical prescriptions and a post hoc ablation estimated what a rule-based policy would have prescribed under different information from mNGS.
Twenty-two of 54 prescriptions (40·7%, 95% CI 28·7-54·0) were potentially actionable: treatment failure prevention 9 (16·7%) and de-escalation 13 (24·1%). Excluding blaEC and blaACT raised cephalosporin specificity from 25·6% to 78·9% with a small tradeoff in sensitivity. NPVs were at least 89·7% for carbapenems, cephalosporins, trimethoprim/sulfamethoxazole, aminoglycosides and the fluoroquinolone classifier reached 100·0% PPV in Escherichia coli. Our refined resistance classification rules achieved a good tradeoff between the risk of ineffective antibiotics and the use of broad-spectrum carbapenem, compared with observed prescribing.
In a high-resistance setting, a same-day mNGS report was potentially actionable for two in five empirical prescriptions, mainly through resistance calling. However, the findings rest on a small number of cases.
PMID:
42874851
Bibliographic data and abstract were imported from PubMed on 15 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 17
- Comments 0